January 28, 2013

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Respiratory viral infections can cause severe pneumonia in lung transplant recipients as well are associated with acute rejection and long-term morbidity with bronchiolitis obliterans syndrome. There are no specific antiviral options for the majority of respiratory viruses. DAS181 is a novel sialidase fusion protein and is administered by inhalation. The authors describe the use of this new antiviral in a lung transplant patient with parainfluenza virus infection requiring ICU admission. The authors obtained this drug under an emergency investigational new drug application. The case report describes clinical and virologic improvement with use of this medication, which was also well-tolerated. Newer therapies for respiratory virus infections are a welcome addition especially for transplant patients where disease is severe and options are limited.

Transplant Infectious Disease

Tags: , ,